Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: | Completed |
---|---|
Conditions: | Neurology, Psychiatric, Psychiatric, Autism |
Therapuetic Areas: | Neurology, Psychiatry / Psychology |
Healthy: | No |
Age Range: | 3 - 17 |
Updated: | 12/23/2018 |
Start Date: | August 1, 2014 |
End Date: | November 30, 2017 |
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
The purpose of this research study is to learn about the effects of supplemental intranasal
oxytocin as a treatment for improving social difficulties in children and adolescents with
autism. This study will also provide additional information about the safety and tolerability
of intranasal oxytocin. Investigators expect oxytocin will increase social motivation,
improving daily living skills and quality of life.
oxytocin as a treatment for improving social difficulties in children and adolescents with
autism. This study will also provide additional information about the safety and tolerability
of intranasal oxytocin. Investigators expect oxytocin will increase social motivation,
improving daily living skills and quality of life.
There is a tremendous unmet need for accessible treatments that address core symptoms of ASD
and are safe for sustained use. The Study of Oxytocin in ASD to improve Reciprocal Social
Behaviors or (SOARS-B) will test a very promising potential treatment−intranasal oxytocin−for
ASD's fundamental social communication deficits in a large, group of verbal and nonverbal
children. SOARS-B will also provide information about the regulation of DNA methylation and
transcription of the oxytocin receptor gene (OXTR), as well as other genes relevant to
oxytocin's CNS activity, as a function of time and in response to oxytocin treatment. These
data will fill a key gap in our understanding of oxytocin's role in ASD and its ability to
alter epigenetic modifications of the OXTR.
and are safe for sustained use. The Study of Oxytocin in ASD to improve Reciprocal Social
Behaviors or (SOARS-B) will test a very promising potential treatment−intranasal oxytocin−for
ASD's fundamental social communication deficits in a large, group of verbal and nonverbal
children. SOARS-B will also provide information about the regulation of DNA methylation and
transcription of the oxytocin receptor gene (OXTR), as well as other genes relevant to
oxytocin's CNS activity, as a function of time and in response to oxytocin treatment. These
data will fill a key gap in our understanding of oxytocin's role in ASD and its ability to
alter epigenetic modifications of the OXTR.
Inclusion Criteria:
- Be between the ages of 3 years 0 months and 17 years 11 months at the time of
randomization
- Be diagnosed by clinician experienced in assessment of ASD with autistic disorder,
Asperger's syndrome, or PDD-NOS using DSM-V-TR criteria
- Must have clinical diagnosis of ASD confirmed using the Autism Diagnostic Observation
Scale (ADOS, Lord et al., 2001)
- Must have clinical diagnosis of ASD confirmed using the Autism Diagnostic
Interview-Revised (ADI-R, Rutter, 2003). ASD criteria proposed by Risi (2006).
Specifically, subject must be within 1 point of autism criteria on both social and
communication domains of the ADI or meet autism criteria in one of these ADI domains
and come within 2 points of autism criteria in the other
- Have a guardian who is able to provide informed consent
- If cognitively able, subject must be able to provide informed assent/consent
Exclusion Criteria:
- Have a known diagnosis of Rett Syndrome or Childhood Disintegrative Disorder, or have
marked sensory impairment such as deafness or blindness
- Have active cardiovascular disease or renal disease that is not controlled by
medication
- Subjects who are pregnant, lactating, or who refuse to practice contraception if
sexually active
- Subjects who have had changes in allied health therapies, behavioral or educational
interventions within the two months prior to randomization other than those associated
with school holidays
- Subjects who have had changes in psychiatric medications within 4 weeks of
randomization
- Subjects who have had previous chronic treatment with oxytocin
- Subjects who have caretakers who are unable to speak English, be consistently present
at visits to report on symptoms, or are otherwise judged as unable to comply with the
protocol by the data collection site team
- Subjects with active seizures within the 6 months preceding screening or baseline.
We found this trial at
7
sites
Durham, North Carolina 27710
Principal Investigator: Simon Gregory, PhD
Click here to add this to my saved trials
Boston, Massachusetts 02114
Principal Investigator: Christopher McDougle, MD
Click here to add this to my saved trials
Durham, North Carolina 27705
Principal Investigator: Linmarie Sikich, MD
Click here to add this to my saved trials
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Alexander Kolevzon, MD
Click here to add this to my saved trials
Seattle, Washington 98101
Principal Investigator: Bryan King, MD
Click here to add this to my saved trials
White Plains, New York 10605
Principal Investigator: Jeremy Veenstra-VanderWeele, MD
Click here to add this to my saved trials